Research found | genes can predict the success rate of arthritis treatment

According to a new study at Queen Mary University in London, the molecular characteristics analysis of the lesion joint tissue may greatly affect whether certain drug therapy is valid for patients with rheumatoid arthritis (RA). The study was published on May 19, 2022 in the magazine of "Nature · Medicine". Researchers have also discovered some genes related to the resistance of most drug therapy, which are usually referred to as refractory diseases, which may be the key to finding new effective drugs to help these patients.

Although in the past few decades, the treatment of arthritis has been greatly improved, a large number of people (about 40%) have no response to specific drug treatment, 5%-20%of patients have Drugs are anti -drug.

Researchers conducted a biopsy-based clinical study of 164 arthritis patients, testing their reactions to Lichell monocyl resistance or Tosizumab-these are two drugs used to treat RA. The original trials published in "Liuye Knife" in 2021 showed that among people with low characteristics of Scholars B cell molecular, only 12%responded to the treatment of B cells (Riccchen Mipida), and 50 %Responds to another drug (Tsseyzumab). When patients have a large number of genetic signs, both drugs are also valid.

As part of the first study of the efficacy and mechanism evaluation (EME) plan of MRC and NIHR, the team of Queen Mary of London also studied the patient's response to any drug treatment. Specialized for them.

On this basis, researchers applied a data analysis technology called machine learning model to develop a computer algorithm that can predict the drug reaction of individual patients. Machine learning algorithms include genetic analysis from biopsy. Compared with models that only use tissue pathology or clinical factors, the effect of predicting which treatment method is best performed well.

The study strongly supports genetic analysis of arthritis biopsy before the expensive so -called biological targeting therapy. This can save a lot of time and money for NHS and society, and help avoid potential unnecessary side effects, joint injuries, and more common results in patients. In addition to affecting the treatment prescription, this test can also reveal who may not respond to any drugs in the current market, emphasizing the necessity of developing alternative drugs.

"Costantino Pitzalis, Professor Versus Arthritis, said:" Before incorporating the treatment of arthritis treatment for patients in the treatment of the patient, the molecular information may always change our way of treating this disease. Patients will benefit from a personalized method. The chance of success is much greater, not the current standardized test and wrong drug prescription. "

"These results are incredible and excited, which proves the potential of our fingering. However, this field is still in its infancy, and more confirmation research is needed to fully realize the commitment of precision medical care in RA."

"These results are also important to find solutions for those who have not helped them current treatment. It is important to understand which specific molecular characteristics affect this and which ways to continue driving these patients' disease activities can help develop new new ones Drugs bring better results and urgent need of pain and pain. "

Incorporating these features into the future diagnosis test will be a necessary step to transform these discovers into conventional clinical care.

- END -